Revenue recognition from Collaboration and License Agreements - Schedule of Deferred Revenue (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2024 USD ($)
Roche | Completion of continuing trials
Disaggregation of Revenue [Line Items]
Balance, Beginning	$ 9,463
Increase in collaboration revenue	41,425
Recognition as revenue, as the result of performance obligations satisfied	(50,888)
Balance, Ending	0
Bristol-Myers Squibb Company | Options to License Undruggable Targets
Disaggregation of Revenue [Line Items]
Balance, Beginning	2,489
Increase in collaboration revenue	100
Recognition as revenue, as the result of performance obligations satisfied	(2,589)
Balance, Ending	$ 0